
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 12, 2015

ELECTROMED, INC.
(Exact Name of Registrant as Specified in Its Charter)

Minnesota
(State or Other Jurisdiction of
Incorporation)

001-34839
(Commission File Number)

41-1732920
(I.R.S. Employer Identification
Number)

500 Sixth Avenue NW
New Prague, MN 56071
(Address of Principal Executive Offices)(Zip Code)

(952) 758-9299
(Registrant's Telephone Number, Including Area Code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 2.02 Results of Operations and Financial Condition

On May 12, 2015, Electromed, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended March 31, 2015. The full text of the press release is attached as Exhibit 99.1.

Item 7.01 Regulation FD

On or about May 12, 2015, the Company dispatched a letter from its chief executive officer to the Company’s shareholders, dated May 12, 2015, updating the Company’s shareholders on recent Company developments. The full text of the shareholder letter is attached as Exhibit 99.2.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits:

- 99.1 Press Release dated May 12, 2015.
- 99.2 Shareholder Letter dated May 12, 2015.

The information contained in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 12, 2015

ELECTROMED, INC.

By: /s/ Jeremy T. Brock

Name: Jeremy T. Brock

Title: Chief Financial Officer

EXHIBIT INDEX

<u>Exhibit Number</u>	<u>Description</u>	<u>Method of Filing</u>
99.1	Press Release dated May 12, 2015	Furnished Electronically
99.2	Shareholder Letter dated May 12, 2015	Furnished Electronically

ELECTROMED, INC.

FOR IMMEDIATE RELEASE

Contact

Jeremy Brock
Chief Financial Officer
Electromed, Inc.
952-758-9299
investorrelations@electromed.com

Electromed, Inc. Reports Higher Third Quarter Revenues and Profits

New Prague, Minnesota – May 12, 2015 - Electromed, Inc. (NYSE MKT: ELMD) today announced financial results for the three- and nine-month periods ended March 31, 2015. Net revenues for the third quarter of fiscal 2015 rose approximately 15% to \$4.56 million, compared to \$3.96 million in the same quarter of fiscal 2014. The Company reported net income of \$37,000, or \$0.00 cents per basic and diluted share, for the third quarter of fiscal 2015, compared to a net loss of \$1,004,000, or (\$0.12) per basic and diluted share, for the same period of fiscal 2014.

Growth in total net revenues was attributable to strong results in the home care market where revenue increased by approximately 18.5%, or \$0.6 million, compared to the same period of fiscal 2014. Home care sales increased due to a greater number of approvals from third party payers, such as insurance companies, Medicare and Medicaid, for the Company's SmartVest™ products. International sales decreased by 44%, or \$128,000, due primarily to the timing of orders placed by international distributors in the first quarter of fiscal 2015. Institutional and government sales increased 30%, or \$131,000, compared to the third quarter of fiscal 2014 as a result of the continued focused efforts of our sales force.

Gross margins in the third quarter of fiscal 2015 were 69.3%, up from 63.7% in the third quarter of fiscal 2014. The increase in gross profit percentage resulted primarily from the increase in domestic home care revenue at higher average selling price and greater referral to approval percentage, as compared with the same period in the prior year. The gross margin was also negatively affected by an impairment charge of \$70,000, taken on tools that became obsolete during the third quarter of fiscal 2015 as we implemented certain improved manufacturing processes that reduce the cost of producing the SmartVest SQL™. Over time, the Company expects to bring manufacturing costs for the SQL product roughly in line with previous products. Operating expenses, which include selling, general and administrative (SG&A) and research and development (R&D), declined to 68% of revenue compared with 69% of revenue in the third quarter of fiscal 2014. The decline resulted from the higher level of net revenues in the third quarter of fiscal 2015. Operating expenses rose slightly as a result of higher sales commission and bonus expenses due to higher revenue and profitability and higher consulting fees for sales training, information technology improvements, and a contract employee.

The Company generated \$558,000 of cash from operations in the third quarter and finished the quarter with over \$2.9 million of cash on hand.

For the nine months ended March 31, 2015, revenue increased 31%, to \$14.2 million, compared to the same period of fiscal 2014. Gross margins were 69.4%, up from 68% in the third quarter of fiscal 2014, while net income increased to \$837,000 or \$0.10 per basic and diluted share compared to a net loss of \$1,579,000, or (\$0.19) per basic and diluted share, in the same period of the prior year.

Electromed, Inc.

Results for the Three-and Nine-Months Ended March 31, 2015

Page 2

Kathleen Skarvan, Electromed's chief executive officer, commented, "I am very pleased that we reported our fourth consecutive profitable quarter and continued to see year-over-year revenue growth. Revenue growth was 15 percent compared to the prior year quarter attributable primarily to growth in home care sales. We continue to see year-over-year new referral growth and increases in the average reimbursement per approved referral. On a sequential quarter comparison, revenue declined due to a decrease in home care approvals primarily attributable to third party payer referral mix. We believe the quarter's lower approvals are not indicative of a longer term trend.

Institutional revenue grew 30% compared to the prior year quarter. While it is a lower percentage of our total revenue, this growth in revenue suggests that our focus on this sales channel is yielding results. We expect to offer the SQL product to institutions during the fourth quarter of fiscal 2015. We believe that the differentiated features of SQL from our previous model, SV2100, may generate interest from institutions that currently utilize a competitor's device.

Cash flow continues to be positive due to process improvement by our reimbursement team and improved collections. I am very proud of the entire Electromed team as they have worked diligently to return Electromed to consistent revenue growth and profitability. They are a talented group with an intense focus on improving the experience patients have with our products. The Electromed team understands that our products have a significant impact on the lives of patients and they approach that responsibility with passion and commitment."

About Electromed, Inc.

Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest[®] Airway Clearance System and related products, to patients with compromised pulmonary function. Further information about the Company can be found at www.electromed.com.

Cautionary Statements

Certain statements found in this release may constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect the speaker's current views with respect to future events and financial performance and include any statement that does not directly relate to a current or historical fact. Forward-looking statements can generally be identified by the words "anticipate," "believe," "expect," "will" and similar words. Forward-looking statements made in this release include the Company's beliefs regarding continued progress in its reimbursement, product launch timing, revenue growth and cost control strategies. Forward-looking statements cannot be guaranteed and actual results may vary materially due to the uncertainties and risks, known and unknown, associated with such statements. Examples of risks and uncertainties for Electromed include, but are not limited to, the impact of emerging and existing competitors, the effect of new legislation on our industry and business, the effectiveness of our sales and marketing and cost control initiatives, changes to reimbursement programs, as well as other factors described from time to time in our reports to the Securities and Exchange Commission (including our Annual Report on Form 10-K). Investors should not consider any list of such factors to be an exhaustive statement of all of the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on "forward-looking statements," as such statements speak only as of the date of this release.

Financial Tables Follow:

-more-

Electromed, Inc.**Results for the Three-and Nine-Months Ended March 31, 2015**

Page 3

**Electromed, Inc. and Subsidiary
Condensed Consolidated Balance Sheets**

	<u>March 31,</u> <u>2015</u>	<u>June 30,</u> <u>2014</u>
	<u>(Unaudited)</u>	
Assets		
Current Assets		
Cash	\$ 2,904,811	\$ 1,502,702
Accounts receivable (net of allowances for doubtful accounts of \$45,000)	6,388,454	6,487,267
Inventories	2,401,864	2,235,496
Prepaid expenses and other current assets	481,477	397,853
Total current assets	<u>12,176,606</u>	<u>10,623,318</u>
Property and equipment, net	3,617,372	3,935,802
Finite-life intangible assets, net	832,520	930,451
Other assets	361,076	302,595
Total assets	<u>\$ 16,987,574</u>	<u>\$ 15,792,166</u>
Liabilities and Equity		
Current Liabilities		
Current maturities of long-term debt	\$ 48,098	\$ 46,375
Accounts payable	684,290	380,582
Accrued compensation	561,938	391,040
Warranty reserve	670,000	700,000
Other accrued liabilities	171,893	302,482
Total current liabilities	<u>2,136,219</u>	<u>1,820,479</u>
Long-term debt, less current maturities	1,214,795	1,251,192
Total liabilities	<u>3,351,014</u>	<u>3,071,671</u>
Commitments and Contingencies		
Equity		
Common stock, \$0.01 par value; authorized: 13,000,000; shares issued and outstanding: 8,133,857 and 8,114,252 at March 31, 2015, June 30, 2014, respectively	81,339	81,143
Additional paid-in capital	13,295,566	13,217,166
Retained earnings (accumulated deficit)	259,655	(577,814)
Total equity	<u>13,636,560</u>	<u>12,720,495</u>
Total liabilities and equity	<u>\$ 16,987,574</u>	<u>\$ 15,792,166</u>

Electromed, Inc.

Results for the Three-and Nine-Months Ended March 31, 2015

Page 4

Electromed, Inc. and Subsidiary
Condensed Consolidated Statements of Operations
(Unaudited)

	For the Three Months Ended March 31,		For the Nine Months Ended March 31,	
	2015	2014	2015	2014
Net revenues	\$ 4,556,977	\$ 3,956,335	\$ 14,209,239	\$ 10,875,588
Cost of revenues	1,400,252	1,436,195	4,354,339	3,476,570
Gross profit	<u>3,156,725</u>	<u>2,520,140</u>	<u>9,854,900</u>	<u>7,399,018</u>
Operating expenses				
Selling, general and administrative	3,020,849	2,634,036	8,714,746	8,097,067
Research and development	78,292	103,166	237,201	405,009
Total operating expenses	<u>3,099,141</u>	<u>2,737,202</u>	<u>8,951,947</u>	<u>8,502,076</u>
Operating income (loss)	<u>57,584</u>	<u>(217,062)</u>	<u>902,953</u>	<u>(1,103,058)</u>
Interest expense, net of interest income of \$371, \$392, \$2,044 and \$11,730 respectively	20,355	23,321	65,484	57,992
Net income (loss) before income taxes	<u>37,229</u>	<u>(240,383)</u>	<u>837,469</u>	<u>(1,161,050)</u>
Income tax expense	—	(764,000)	—	(418,000)
Net Income (loss)	<u>\$ 37,229</u>	<u>\$ (1,004,383)</u>	<u>\$ 837,469</u>	<u>\$ (1,579,050)</u>
Income (loss) per share:				
Basic	<u>\$.00</u>	<u>\$ (0.12)</u>	<u>\$.10</u>	<u>\$ (0.19)</u>
Diluted	<u>\$.00</u>	<u>\$ (0.12)</u>	<u>\$.10</u>	<u>\$ (0.19)</u>
Weighted-average common shares outstanding:				
Basic	<u>8,114,252</u>	<u>8,114,252</u>	<u>8,114,252</u>	<u>8,114,252</u>
Diluted	<u>8,166,659</u>	<u>8,114,252</u>	<u>8,131,496</u>	<u>8,114,252</u>

Electromed, Inc.

Results for the Three-and Nine-Months Ended March 31, 2015

Page 5

Electromed, Inc. and Subsidiary
Condensed Consolidated Statements of Cash Flows
(Unaudited)

	For the Nine Months Ended March 31,	
	2015	2014
Cash Flows From Operating Activities		
Net income (loss)	\$ 837,469	\$ (1,579,050)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:		
Depreciation	459,223	409,651
Amortization of finite-life intangible assets	97,931	95,082
Amortization of debt issuance costs	14,546	13,078
Share-based compensation expense	78,596	73,821
Deferred income taxes	—	454,000
Loss on disposal of property and equipment	233,116	34,110
Changes in operating assets and liabilities:		
Accounts receivable	98,813	2,544,116
Inventories	(166,368)	(1,171,221)
Prepaid expenses and other assets	(141,854)	(37,930)
Accounts payable and accrued liabilities	319,717	184,333
Net cash provided by operating activities	<u>1,831,189</u>	<u>1,019,990</u>
Cash Flows From Investing Activities		
Expenditures for property and equipment	(379,609)	(626,327)
Expenditures for finite-life intangible assets	—	(8,155)
Net cash used in investing activities	<u>(379,609)</u>	<u>(634,482)</u>
Cash Flows From Financing Activities		
Principal payments on long-term debt including capital lease obligations	(34,674)	(81,348)
Payments of deferred financing fees	(14,797)	(35,296)
Net cash used in financing activities	<u>(49,471)</u>	<u>(116,644)</u>
Net increase in cash and cash equivalents	1,402,109	268,864
Cash and cash equivalents		
Beginning of period	1,502,702	503,564
End of period	<u>\$ 2,904,811</u>	<u>\$ 772,428</u>

Electromed, Inc.

FY2015 Q3 Letter to Shareholders

Making life's important moments possible – one breath at a time.®

To our shareholders

It is my pleasure to be writing to you to discuss the Company's results for the third quarter of fiscal 2015, our outlook for the balance of the year and our strategies for continued growth and profit improvement. The third quarter was the fourth consecutive quarter in which we reported a net profit and we continued to show solid growth in revenues. Net revenues were up 15.2% over the third quarter of fiscal 2014 to \$4.6 million and we reported a profit of \$37,000. For the first nine months of fiscal 2015, net revenues rose 30.7% to \$14.2 million and we reported net income of \$0.10 per share compared to a loss of \$0.19 per share in the first nine months of fiscal 2014.

Gross margin the third quarter of fiscal 2015 was 69.3% compared to 63.7% in the year earlier third quarter and was consistent with the first two quarters of fiscal 2015. We believe we can improve gross margins further as we reduce the manufacturing cost of the SmartVest® SQL®, the Company's newest product.

Selling, general and administrative expenses rose 14.7% in the quarter due in part to timing of certain annual fees and higher professional fees. We will continue to manage operating expenses carefully and expect to gain leverage as we grow revenues. Referrals showed strength as we exited the quarter and realize the benefits of earlier investments in sales training, time and territory management, and hiring more experienced sales people through the replacement of low performers. We are expanding the sales team in the fourth quarter to provide greater focus in denser populated regions of the United States, enhancing our ability to grow revenues over the longer term.

While revenue growth was solid, it did slow somewhat from the rates of growth we saw in the first and second quarters of fiscal 2015. Total revenue growth in the home care business was 18.5% compared to the third quarter of the prior fiscal year, but declined on a sequential basis. This was largely due to an increase in average reimbursement per approval compared to the prior year combined with a decrease in approvals compared to the prior quarter. The sequential decrease in approvals was primarily attributable to the referral mix and not indicative of a longer term trend. As a reminder, there are a number of factors that may affect approvals. Some examples include diagnoses that are not assured of reimbursement and whether the individual patient meets medical criteria for reimbursement. With the improved productivity of our sales people, our sales team expansion plans and continued strong performance by our reimbursement team, we again expect to see sequential growth in home care revenue.

Sales to institutions were strong in the third quarter of fiscal 2015, with revenue up 30% to \$571,000 compared to the year earlier quarter. Institutional sales are important for us as patients are often introduced to high frequency chest wall oscillation (HFCWO) therapy in an institutional setting and then are prescribed a device to use at home when they are discharged.

Cash flow continued to be positive in the third quarter with cash flow from operations of over \$500,000 and we ended the quarter with \$2.9 million in cash on our balance sheet. The Company's finances are the healthiest they have been in some time and provide us the resources we need to grow and build the business.


In last quarter's letter, I noted that SQL continues to receive positive feedback from physicians, clinicians and patients, and we believe it is the most attractive HFCWO product in the market. I also noted that it can take time to gain traction in a clinic as practitioners often become comfortable with a product and tend to consistently prescribe that product. We have seen indications in the last few months that our sales efforts are beginning to bear fruit as referrals have been trending above the previous year's levels. While it is still early to describe this as a trend shift, the evidence to date is encouraging.

We are excited about the future opportunities in the HFCWO market. Some market research suggests the aging population and better diagnostic techniques could reveal a significantly larger group of patients suffering with bronchiectasis and related conditions. These patients have damaged airways which make them excellent candidates for HFCWO therapy and our SQL offering is an ideal solution. We believe the total addressable market might be several times larger than what is currently assumed and we are positioning the Company to capture more of that market as it becomes available. This is an exciting time for Electromed!

I am very proud of the entire Electromed team as they have overcome numerous obstacles to return the Company to consistent revenue growth and profitability. They are a talented group with an intense focus on improving the experience patients have with our products. The Electromed team understands that our products have a significant impact on the lives of patients and they approach that responsibility with passion and commitment.

Thank you, shareholders, for your continued support.

Sincerely,



Kathleen Skarvan

Chief Executive Officer

Cautionary Statements

Certain statements found in this release may constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect the speaker's current views with respect to future events and financial performance and include any statement that does not directly relate to a current or historical fact. Forward-looking statements can generally be identified by the words "anticipate," "believe," "expect," "will" and similar words. Forward-looking statements made in this release include the Company's beliefs regarding continued progress in its reimbursement, product launch timing, revenue growth and cost control strategies. Forward-looking statements cannot be guaranteed and actual results may vary materially due to the uncertainties and risks, known and unknown, associated with such statements. Examples of risks and uncertainties for Electromed include, but are not limited to, the impact of emerging and existing competitors, the effect of new legislation on our industry and business, the effectiveness of our sales and marketing and cost control initiatives, changes to reimbursement programs, as well as other factors described from time to time in our reports to the Securities and Exchange Commission (including our Annual Report on Form 10-K). Investors should not consider any list of such factors to be an exhaustive statement of all of the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on "forward-looking statements," as such statements speak only as of the date of this release.
